title: [The influence of benign prostatic hyperplasia drugs on incidence and pathology grading of prostate cancer].
abstract: OBJECTIVE
  To analyze the influence of benign prostatic hyperplasia (BPH) drugs on incidence and pathology grading of prostate cancer in China.
  
  
  METHODS
  Retrospectively investigated the history of drug treatment in 1029 cases of BPH in patients from February 1998 to December 2004. According to the history of drug use, the patients were divided into 4 groups: finasteride group, alpha-receptor inhibitor group, finasteride and alpha-receptor inhibitor combination group and control group (untreated group). We gathered pathology sections of patients in all groups, and gave Gleason Score to each. The difference of incidence and pathology grading of prostate cancer were analyzed by Stata 7.0.
  
  
  RESULTS
  The incidence of prostate cancer in the population of our study was 13.5%; The incidence in finasteride group, alpha-receptor inhibitor group, combination group and control group was 9.8%, 16.0%, 10.3% and 18.6%, respectively. There was significant difference between the two groups with the use of finasteride and the two groups without it (P < 0.05). In our study, the ratio of middle or high level pathology grading (Gleason ≥ 7) in prostate cancer patients was 58.3%, the ratio of middle or high level pathology grading prostate cancer patients in the four groups was 71.4%, 59.6%, 67.7% and 40.0%, respectively. In the comparison of composition ratio of middle or high level prostate cancer, there was significant difference between the two groups with the use of finasteride and the two groups without it (P < 0.05).
  
  
  CONCLUSIONS
  Finasteride can lower the risk of prostate cancer, but increase the pathology grade of the prostate cancer which has occurred in the same time. The alpha-receptor inhibitor does not have the same effect.
authors.affiliation: Department of Urology, General Hospital of the People's Liberation Army, Beijing 100853, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Zhu
authors.forename: Jiang-ping
authors.initials: JP
authors.lastname: Gao
authors.forename: A-xiang
authors.initials: AX
authors.lastname: Xu
authors.forename: Xian-yu
authors.initials: XY
authors.lastname: Lü
authors.forename: Liang
authors.initials: L
authors.lastname: Cui
authors.forename: Bao-fa
authors.initials: BF
authors.lastname: Hong
authors.forename: Xu
authors.initials: X
authors.lastname: Zhang
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000473:pathology; D012189:Retrospective Studies
chemical_list: D000317:Adrenergic alpha-Antagonists; D018120:Finasteride